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Abstract:  
 
Both patients and physicians prefer the oral route of drug delivery.  The 
gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics 
because of its protease and bacteria-rich environment as well as general pH 
variability from pH 1-7.  These extreme environments make oral delivery 
particularly challenging for the biologic class of therapeutics.  Here we 
demonstrate proof-of-concept experiments in swine that microneedle-based 
delivery has the capacity for improved bioavailability of a biologically-active 
macromolecule.  Moreover, we show that microneedle-containing devices can be 
passed and excreted from the GI tract safely.  These findings strongly support 
the success of implementation of microneedle technology for use in the GI tract. 
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INTRODUCTION 
 
Oral drug administration remains the preferred method particularly when 
compared to parenteral routes1,2.  Oral drug delivery, however, is limited by poor 
drug absorption and drug degradation. This is of particular concern for the 
biologic class of drugs (such as insulin, monoclonal antibodies and nucleic 
acids), which are susceptible to proteases, endonucleases, bacteria, and the 
extremes in pH encountered in the GI tract3.  As a result, biologics are not 
currently orally administrable and require delivery through injection.  Several 
approaches have been pursued in an attempt to enable oral administration of 
biologics, including co-administration with enzyme inhibitors, chemical 
modification of the drug, polymeric micro- and nano- carriers, liposome carriers, 
as well as targeted nanoparticles4-6.  However, these approaches require 
reformulation of the active pharmaceutical ingredient (API) to ensure both 
compatibility with the specific technique and that the activity of the API is 
maintained.  Physical methods of administration provide an alternative means of 
delivery, requiring minimal reformulation of the drug, providing a potentially broad 
delivery platform.  Similarly, these methods have the potential to deliver 
macromolecules.  Microneedle-based technology has been extensively evaluated 
for transdermal drug and vaccine delivery7 to many parts of the body, including 
the perianal skin area for the treatment of fecal incontinence8.  Unlike the skin, 
the GI tract is insensate and therefore provides a unique opportunity for the use 
of needle-based delivery systems.  Moreover the likelihood of efficacy and safety 
of delivery across the GI barrier with needles is supported by the extensive 
gastroenterological experience with GI mucosal injection as well as by the 
literature on the ingestion of foreign objects. Epinephrine injections in the GI tract 
are part of the standard of care with respect to the treatment of bleeding ulcers 
as well as polypectomy-induced GI bleeding9.  Despite being used for localized 
vasoconstriction of bleeding vessels at ulcer sites, a common observation during 
these procedures is a near immediate tachycardic response in the patient9, 
supporting the systemic bioavailability of epinephrine when administered via the 
GI mucosa10.  With regards to safety, inadvertent or purposeful ingestion of sharp 
and foreign objects has helped establish clinical guidelines with respect to object 
characteristics and object length for risk stratification of clinical complications and 
therefore guidance for clinical management11.  Surprisingly, the overwhelming 
majority of foreign objects, including sharp objects, are capable of being passed 
via the GI tract without complications 12. A large case series of 542 patients 
reporting the ingestion of foreign bodies noted that in those patients where 
foreign bodies were retained and surgical removal was required, the size range 
of the objects was large; approximately 3-16cm13  well above the size range of 
needles used in the proposed ingestible devices.  Taken together, these prior 
observations would suggest that drug delivery may be possible from a capsule 
containing needles in a safe manner.  Specifically, one could imagine an 
ingestible capsule containing radially protruding microneedles that could be used 
as a platform for the oral delivery of a broad range of therapeutics currently 
limited to injection (Figure 1).   This presents an unexplored mode of drug 
administration.  To motivate further development of this technology, such a 
device would need to 1) demonstrate acceptable bioavailability comparable to 
that achieved through standard injection and 2) safely pass through the GI tract.  
To address these two critical issues, here we investigate the bioavailability of a 
model biologic macromolecule (insulin) via the GI tract and compare these to the 
kinetics achieved through traditional subcutaneous injection. We then examine 
the safety and feasibility of passing a model device, as well as its approximate 
retention time, for the purpose of guiding the design of subsequent microneedle-
based GI drug delivery systems. 
 
MATERIALS AND METHODS 
Device Design and Construction 
Computer aided design software (Solidworks, Dassault Systemes, 
Waltham MA) was utilized for the design of the prototype for safety evaluation 
(Figure 1A).  This was fabricated from clear acrylic and 25G needles protruding 
5mm from the surface were fitted manually into the orifices.  The device was 2cm 
in length and 1cm in diameter.  A central metallic core was included for 
increasing the radio-opacity for rapid radiographic detection of the device. 
 
In Vivo Insulin Delivery 
All procedures were conducted in accordance with protocols approved by 
the Massachusetts Institute of Technology Committee on Animal Care.  Insulin 
was chosen as a model biologic because it is recognized to have negligible oral 
bioavailability.  It also induces a rapid physiological response (reduction of blood 
glucose), which can be readily monitored and quantified in real-time.  In vivo 
porcine studies were performed on 3 Yorkshire pigs weighing approximately 75-
80kg.  Prior to the procedures, the animals were fasted overnight.  On the day of 
the procedure, the morning feed was withheld and the animal was sedated. 
Following induction of anesthesia with intramuscular injection of Telazol 
(tiletamine/zolazepam) 5mg/kg, xylazine 2mg/kg, and atropine 0.04 mg/kg, the 
pigs were intubated and maintained on isoflurane (1-3% inhaled).   After 
sedation, a catheter was placed in the femoral vein using the Seldinger technique 
to allow for frequent blood sampling.  Prior to administration of insulin, 4mL blood 
samples were taken from the catheter in the femoral vein to quantify the animal’s 
starting blood-glucose levels.  A real-time readout was achieved using a 
TRUEtrack® blood glucose meter (Nipro Diagnostics Inc., Fort Lauderdale, FL) 
and the remainder of the blood sample was saved in a blood collection tube with 
sodium fluoride and EDTA to minimize further glucose metabolism (Beckton 
Dickinson, Franklin Lakes, NJ).  All data shown represents the blood-glucose 
values quantified from the blood collection tubes.  
 
Following baseline blood collections to establish an initial blood-glucose 
level, 10 units of rapid acting insulin aspart (NovoLog, Novonordisk, Bagsværd, 
Denmark)  in 1ml of 0.9% saline was administered using a 25G Carr-Locke 
Needle (US Endoscopy, Mentor, OH).  Injections were performed in triplicate on 
separate experimental days in the stomach, duodenum, colon and skin. A 
submucosal injection was confirmed via direct endoscopic visualization of a 
submucosal expansion. Colonic injection was preceded by a tap water enema to 
facilitate tissue visualization.  Subcutaneous injections were performed using a 
25G needle in the anterior abdominal wall of the animal.  It should be noted that 
only one injection in one tissue area was administered to an animal on a given 
day.  Upon injection, blood was sampled from the catheter approximately every 
two minutes and analyzed as described above.  The animal’s blood-glucose was 
monitored in this way until no further drop occurred or until a blood-glucose 
concentration of 40mg/dL was achieved in order not to harm the animal.  
Persistent hypoglycemia under 40mg/dL was corrected with intravenous boluses 
of 50% dextrose. Blood-glucose values presented are normalized by the animal’s 
initial value, defined as the last blood-glucose value observed before injection of 
insulin.    
 
Evaluation of Device Passage and Safety Assessment 
To place the prototype shown in Figure 1B, the animal was first sedated 
and intubated as described above.  Then, an overtube (US Endoscopy, Mentor, 
Ohio)  was placed in the esophagus.  The microneedle pill was deployed in the 
stomach under direct endoscopic visualization.  Placement was further confirmed 
radiographically.  The animals were evaluated clinically twice daily for any 
evidence of obstruction including abdominal distension, lack of fecal material in 
the cage and vomiting while evidence of the device remained radiographically 
visible.  Radiographs were performed every 48-72 hours.  The retention time of 
the device was estimated based on when it was no longer visible on radiographs.  
Post mortem inspection of the entire GI tract confirmed passage of the device.  
The GI tissue was evaluated for any macroscopic evidence of damage.  
Furthermore, sections were taken from the pylorus, ileocecal valve and anal 
canal, representing the three points of constriction distal to the stomach, and 
evaluated for any evidence of macroscopic and microscopic damage through 
analysis of hematoxylin and eosin-stained tissue sections. 
 
Statistical Analysis 
The time necessary to observe a drop in the animal’s blood-glucose as a 
result of insulin administration was defined as a drop in initial blood-glucose ≥ 
5%.  Insulin administration in each tissue was repeated on separate days at least 
three times. 
 
Statistical significance was assessed by one-way ANOVA. Statistical 
significance is defined as P < 0.05.  All calculations were performed using 
MatLab R2014a (MathWorks, Natick, MA). 
 
RESULTS 
 
Systemic Delivery of Insulin 
The ability for systemic delivery of insulin was evaluated through serial 
injections via the gastric, duodenal and colonic mucosa of approximately 75-80kg 
Yorkshire pigs. Subcutaneous insulin administration was used as a comparator 
(Figure 2A).  The induction of hypoglycemia was monitored following the 
administration of insulin, and the time to hypoglycemic onset (defined as a drop 
in the initial blood-glucose ≥ 5%) was used for comparison across the varying 
anatomic sites (Figure 2B-D).  Hypoglycemic onset following the injection of 10 
units of rapid acting insulin was observed at 23.08 +/- 7.00, 6.28 +/- 4.48, 6.66 +/- 
1.65 and 16.91 +/- 6.39 minutes for subcutaneous, gastric, duodenal and colonic 
administration, respectively. The onset time was significantly diminished when 
insulin was administered via the GI tract as compared to traditional subcutaneous 
administration (Figure 2B-D).  While the average onset time via the colon was 
shorter than that observed via the skin, the difference was not statistically 
significant.  However, administration via the gastric and duodenal mucosa 
demonstrated a significant reduction in the onset time compared to 
subcutaneous administration (P < 0.008). 
 
Safety Evaluation of a Microneedle Prototype in the Gastrointestinal Tract 
The safety and ability for natural passage of a microneedle-containing 
device via the GI tract was investigated.  Safety and passage time was estimated 
using the custom-built device shown in Figure 1B.  The dimensions of this 
prototype were modeled around those of FDA-approved ingestible devices, such 
as the video capsule endoscope14. The microneedles were placed radially 
around the device to ensure maximal apposition of the needles with the GI 
mucosa. A metal core was added to aid in the visualization of the pill on 
radiographs (Figure 1C). 
 
The device was endoscopically deployed in the stomach of three animals 
as shown in Figure 3A.   The animals were monitored daily and radiographs were 
taken to track the pill movement and to monitor for any evidence of intestinal 
obstruction or perforation (Figure 3B).  Throughout the transit time of the 
prototype, all animals remained free of clinical signs of obstruction.  Furthermore, 
radiographs remained free of evidence of intestinal obstruction or perforation.  
Loss of a detectable radiopaque device on the radiographs was used to 
determine the approximate transit time of the prototypes.  The passage time of 
the device in three different animals was 7, 19, and 56 days.  Upon loss of the 
radiopaque device, the animals were euthanized, and the entire GI tract was 
examined and found to be macroscopically normal.  Further, the three sites of 
constriction in the GI tract distal to the site of prototype deployment (pylorus, 
ileocecal valve, and anal canal) were examined and appeared normal (Figure 
3C-E). Additionally, these three points were also fixed in formalin for histological 
examination (Figure 3C-E).  Histological examination was notable for normal 
appearing tissue at all three sites of constriction in the GI tract in the three 
animals.  
  
DISCUSSION 
 
Here we report in vivo proof-of-concept experiments supporting the 
feasibility and safety of microneedle-based trans-GI delivery of a macromolecule.  
With regards to bioavailability, delivery was found to be more effective than 
subcutaneous administration.  Specifically, GI-based delivery afforded improved 
pharmacokinetics and a more robust hypoglycemic effect.  Because of the 
extensive investigation into the use of microneedles for transdermal delivery, we 
compared these results to recent literature reports of microneedle-based 
transdermal delivery of insulin15-17. To compare delivery routes, the 
subcutaneous administration of insulin included in each study was used as a 
control.  Then, the efficacy of each route relative to its respective subcutaneous 
control was assessed and compared qualitatively.  This was done to account for 
differences in experimental methods across studies.  In the transdermal studies, 
subcutaneous administration always afforded a faster hypoglycemic onset time 
compared to microneedle-based transdermal delivery of insulin. Even when 
multiple techniques were employed transdermally (microneedles and 
iontophoresis), subcutaneous administration afforded a faster onset time.  This 
should be contrasted with the findings presented here, where microneedle-based 
trans-GI delivery affords faster onset compared to subcutaneous injection.   Not 
having to use multiple techniques also greatly simplifies administration15-17.  
While the bioavailability presented here is likely to be higher than that from a 
fully-integrated microneedle capsule, it was critical to first demonstrate the 
bioavailability of therapeutics administered in this way to confirm this mode of 
administration as adequate for the delivery of macromolecules. There are many 
possible avenues of exploration surrounding the bioavailability achieved from a 
stand-alone device.  For example, solid, drug-containing microneedles could be 
fabricated from biocompatible polymers.  These could then detach from the 
capsule and become lodged in the GI tissue, where they could slowly release 
their payload (Figure 4). Additionally, the peristaltic motion in the GI tract could 
be utilized to compress the capsule, leading to release of drug only when the 
tissue is in immediate contact with the needles.  Evaluation of the drug release 
kinetics and the kinetics of clearance of the device as a result of varying 
microneedle geometries will be required to fully characterize future iterations of 
devices supported by this work.   
 
In addition to the bioavailability of compounds administered in this way, 
the safety and natural passage of such a device is paramount to further 
investigation.  To this end, safety evaluation in the swine model confirmed the 
absence of any intestinal obstruction or GI mucosal damage and demonstrated 
the ability to pass such a device.  Additionally, histological examination was 
notable for normal GI mucosa at the three distal points of constriction, which are 
at greatest risk for damage.  It should be noted that 25 gauge needles were 
purposefully used for the device shown in Figure 1B.  These needles have an 
outer diameter exceeding 500 μm, increasing the likelihood of perforation.  The 
safe passage of this particular prototype, therefore, is reassuring and further 
indicative of the potential for this new method of macromolecule delivery to be 
safe.   
 
With respect to retention time in our experiments our device was retained 
for a minimum of 7 days.  Typical GI retention times in pigs have previously been 
reported to range from 2 to 33 days18,19. The large range in observed retention 
times of the device in this study may be attributed to the increased interaction 
between the microneedles and the GI mucosa but may also reflect the transient 
gastric retention of the device.  Specifically, the retention time of objects in the 
stomach of pigs has previously been estimated to range from 1 to 28 days18,19 . 
This could be due to the quadrupedal nature. It has also been noted that gastric 
retention scales with object size20. As a result, the geometry and design of the 
microneedles would be another interesting area of investigation for their effect on 
retention time. The safety and tolerability of this device over an extended period 
of time, however, is encouraging and raises the possibility of using derivatives of 
this device for extended release oral formulations of both small molecule 
therapeutics as well as biologics with once a week dosing based on the minimum 
retention time of 7 days that we observed.  Further elucidation of the parameters 
determining consistent retention at varying time points will help develop future 
extended drug release systems.  Taken together, this work will serve as the 
catalyst for a significant change in the development of oral delivery systems for 
macromolecules enabling the bypassing of the harsh GI mucosal environment. 
 
CONCLUSION 
 
The oral route of drug administration is the most convenient route for 
patients1,2. However, the hostile environment present in the GI tract limits oral 
delivery to small molecules.  As a result, the biologic class of drugs is mainly 
limited to needle-based administration.  Physical delivery methods, such as 
microneedles, might enable a platform technology for the oral delivery of a broad 
range of substances.  To this end, here we present a proof-of-concept study 
involving the use of microneedles for the delivery of biologics via the GI tract for 
the first time.  The blood-glucose response kinetics of a model macromolecule, 
insulin, was significantly improved compared to the subcutaneous route when 
administered via the GI tract, demonstrating that the bioavailability of a model 
compound is still sufficient when administered via injection in the GI tract.  To 
investigate the potential tolerability of such a device, results surrounding the safe 
passage of such a device were presented.  Specifically, a model device having 
exposed radially-protruding microneedles was safely passed via the GI tract 
without any evidence of tissue damage. With additional investigation, we 
anticipate multiple variations of devices enabling the oral administration of 
therapeutics from capsules containing microneedles.  These include utilizing the 
peristaltic motion of the GI tract to stimulate microinjection using hollow 
microneedles, or needle dislodgement where the needles are fabricated from 
drug-loaded polymers (Figure 4). By demonstrating the potential safety and 
efficacy of this method, this study provides the basis for further development of 
integrated microneedle devices for oral macromolecule delivery. 
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FIGURE LEGENDS 
 
Figure 1: A cylindrical microneedle pill for the oral administration of biologic 
drugs. (A) Computer-aided design of the radial prototype housing used for in vivo 
safety evaluation. (B) Finished prototype used for in vivo safety showing the 
metal endcap and pin. (C) Radiography of the prototype in (B).  Pill length 2cm, 
diameter 1cm, needle gauge – 25G. 
 
Figure 2:  (A) Images of insulin injection in three different regions of the GI tract 
compared to subcutaneous administration.  Clockwise from upper left: skin, 
stomach, colon, and duodenum.    Representative images of the injections are 
shown.  (B) Time in minutes to observe a drop in blood-glucose as a result of 
injection of insulin in the various GI tissue and skin.  The median, 25th, and 75th 
percentiles are given.  The whiskers indicate the most extreme data points. (C) 
Representative plots of normalized blood-glucose with time as a result of insulin 
injection subcutaneously, or through the stomach, duodenum, or colon. (D) Time 
in minutes to observe a drop in blood-glucose as a result of injection of insulin in 
the various GI tissue and skin.  Averages and standard deviations are given.  (*) 
indicates statistical significance compared to skin based on a multiple 
comparisons test from the ANOVA (p < 0.008). 
 
Figure 3: Safety assessment surrounding passage of the microneedle pill.  (A) 
Endoscopic deployment of the device in the stomach.  (B) X-rays are taken to 
monitor the progression of the pill.  Representative gross and histological images 
of the (C) pylorus, (D) ileocecal valve, and (E) anal valve after natural passage of 
the device.  The scale bar in the histology images represents 1 mm. 
 
Figure 4:  Therapeutic use concept of the microneedle pill.  Both hollow and 
solid microneedles could be used.  In both cases, the pill’s needles are initially 
coated by a pH-responsive coating to aid in ingestion (left).  When the pill has 
reached the desired location in the GI tract, the coating dissolves, revealing the 
microneedles (middle).  In the case of hollow microneedles (top right), the drug 
reservoir is compressed through peristalsis, releasing the drug through the 
needles. In the case of solid microneedles (bottom right), the drug is formulated 
into the microneedles.  The microneedles penetrate the tissue and break off of 
the pill, leaving the needle to release the drug in a controlled manner, based on 
the needle formulation.  
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